Company Overview and News

0
PTL Enterprises Limited - Shareholders meeting

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - Financial Result Updates

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - Shareholders meeting

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - Outcome of Board Meeting

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - Dividend

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - AGM/Book Closure

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - Financial Result Updates

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

34
Market Live: Sensex dips over 150 pts, Nifty breaks 10,550; rupee falls to 66.80/$, Europe down

2018-04-25 moneycontrol
2:40 pm Rupee Update: The Indian rupee extended fall to 66.80 against the US dollar, down 42 paise from previous closing of 66.38 a dollar on bouts of month-end dollar demand from importers amid crude price volatility and rising US bond yields.
500249 JIPKY ICLQY 511389 532832 533179 532960 5225 534816 UCLQY 509220 SBAZ GICHSGFIN ATFL SYNGENE 500215 VOD 532508 539268 STRTECH 511676 532822 ULTRACEMCO SRLRY 500182 FORTIS 500180 KSBPUMPS Q0F PTL IBREALEST BHRYY 512573 532538 BHRQY VIDEOIND IDBLZ 532187 INFRATEL HDFCBANK HEROMOTOCO JSL BHARTIARTL IHHHF AVANTI VOD INDUSINDBK IBVENTURES IBN UCLQF JPASSOCIAT 532843 532532 532454 ICICIBANK 532374 VODPF HDB 532174 IDEA HRTQY PERSISTENT

19
Market Live: Sensex remains weak, but IT stocks extend gain after rupee falls to 66.74/$

2018-04-25 moneycontrol
1:02 pm Economic Growth: Indian economy is expected to witness a cyclical recovery driven by investments as well as consumption, and the average GDP growth is expected to rise to 7.8 percent in the first half of this year, says a report.
BHRYY 500249 JIPKY 512573 532538 ICLQY BHRQY 532832 511389 VIDEOIND IDBLZ 532960 5225 534816 UCLQY 509220 HEROMOTOCO JSL INFRATEL BHARTIARTL IHHHF SBAZ ATFL SYNGENE 500215 VOD VOD AVANTI IBVENTURES 532508 539268 JPASSOCIAT UCLQF 532822 532843 ULTRACEMCO 532532 500182 532454 VODPF FORTIS IDEA HRTQY KSBPUMPS Q0F PTL IBREALEST

19
Market Live: Nifty below 10,600 amid consolidation; Wipro gains ahead of earnings

2018-04-25 moneycontrol
11:55 am Merger Approval: Bhageria Industries informed BSE that the National Company Law Tribunal [NCLT), Mumbai has approved the scheme of Amalgamation of Nipur Chemicals Limited with the company.
BHRYY 500249 JIPKY 512573 532538 ICLQY BHRQY 532832 IDBLZ 532960 5225 534816 UCLQY 509220 HEROMOTOCO JSL INFRATEL BHARTIARTL IHHHF SBAZ ATFL SYNGENE 500215 VOD VOD AVANTI IBVENTURES 532508 539268 JPASSOCIAT UCLQF 532822 532843 ULTRACEMCO 532532 500182 532454 VODPF FORTIS IDEA HRTQY KSBPUMPS Q0F PTL IBREALEST

0
PTL Enterprises Limited - Committee Meeting Updates

2018-04-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

0
PTL Enterprises Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509220 PTL

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...